Vascular GLP‐1 receptor, a target of T2D‐therapy, and TCF7L2 expression were significantly downregulated in obese subjects, indicating that TCF7L2 modulates vascular GLP‐1 receptor expression (Kimura et al., 2018). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.